SuperworthTranscode Therapeutics shares outstanding RNAZ
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 957.2K
- On a year earlier
- +14.8%
- more shares
Transcode Therapeutics had 957.2K diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 14.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2022 | 18 | +1% |
| FY2021 | 17 | +177% |
| FY2020 | 6 | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 957.2K | +15% | |
| Q1 FY26 | 917K | +432% | |
| Q3 FY25 | 833.7K | +5146% | |
| Q2 FY25 | 833.7K | +10825% | |
| Q1 FY25 | 172.3K | +2995% | |
| Q3 FY24 | 15.9K | +13322% | |
| Q2 FY24 | 7.6K | +23023% | |
| Q1 FY24 | 5.6K | +27558% | |
| Q3 FY23 | 118 | +574% | |
| Q2 FY23 | 33 | +88% | |
| Q1 FY23 | 20 | +15% | |
| Q4 FY22 | 18 | +1% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Transcode Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.